文献速递腹部介入CT

经导管动脉化疗栓塞治疗肝细胞癌的灌注衍生疗效评估剂量优化:容积灌注CT与碘浓度比较

Dose Optimization of Perfusion-derived Response Assessment in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: Comparison of Volume Perfusion CT and Iodine Concentration.
PubMed 文献 · Acad Radiol · 2018-10-25

研究回顾性分析32例患者41个肝细胞癌病灶TACE前后影像,比较碘浓度与容积灌注CT参数评估疗效的价值。应答病灶TACE后碘浓度和血流量显著下降,非应答病灶几乎不变;碘浓度鉴别应答的敏感度/特异度为96.7%/81.8%,且碘图辐射剂量低。

要点

  • 应答病灶TACE后碘浓度由131.2 mg/100 mL降至25.6 mg/100 mL(P < 0.001)。
  • 非应答病灶TACE前后碘浓度与血流量变化无统计学显著差异。
  • 碘浓度鉴别应答的敏感度/特异度为96.7%/81.8%,碘图容积CT剂量指数4.9 mGy。

核心结论

  • 碘浓度是肝细胞癌局部治疗疗效监测中有意义的灌注标志物,可以低辐射剂量获得,对双能和单能CT的进一步疗效评估应用有重要意义。

研究设计与样本

  • 回顾性分析32例患者41个肝细胞癌病灶,于TACE前后行容积灌注CT检查,以改良RECIST为标准疗效标准,计算灌注参数和碘图并与标准比较。

关键影像表现/征象

  • 应答病灶TACE前平均碘浓度131.2 mg/100 mL、血流量96.7 mL/100 mL/min,TACE后降至碘浓度25.6 mg/100 mL(P < 0.001)、血流量28.5 mL/100 mL/min(P < 0.001)。
  • 非应答病灶TACE前平均血流量79.3 mL/100 mL/min、平均碘浓度90.4 mg/100 mL,TACE后平均血流量71.3 mL/100 mL/min(无统计学显著差异)、平均碘浓度105.4 mg/100 mL(无统计学显著差异)。

诊断标准与关键数值

  • 以改良RECIST为标准,碘浓度值鉴别应答的敏感度/特异度为96.7%/81.8%。
  • 碘浓度与容积灌注CT参数呈强正相关。

临床应用与阅片要点

  • 容积灌注CT的平均容积CT剂量指数为63.4 mGy,碘图为4.9 mGy,碘图可在较低辐射剂量下获得。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: We assessed the value of iodine concentration (IC) as a perfusion-derived response marker for hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) in comparison with volume perfusion computed tomography (VPCT) parameters.

MATERIALS AND METHODS: Forty-one HCC lesions in 32 patients examined before and after TACE were analyzed retrospectively. VPCT-parameters were calculated and lesion iodine-maps were computed using subtraction of the baseline and the scan 7 seconds after aortic peak enhancement from the corresponding 80 kVp-VPCT data set. Modified RECIST was used as standard response criteria. Comparisons were performed using Student's t test for normal distributed data and Mann-Whitney U test for non-normal distributed data. Additionally, correlation analysis, receiver operating characteristics (ROC) and interreader agreement were assessed.

RESULTS: In responding lesions, mean pre-TACE IC and blood flow (BF) were 131.2 mg/100 mL and 96.7 mL/100 mL/min, decreasing to IC 25.6 mg/100 mL (P < 0.001) and BF 28.5 mL/100 mL/min (P < 0.001) post-TACE. In nonresponding lesions, the values remained almost unchanged: pre-TACE: mean BF 79.3 mL/100 mL/min and mean IC 90.4 mg/100 mL; post-TACE: mean BF 71.3 mL/100 mL/min (n.s.) and mean IC 105.4 mg/100 mL (n.s.). Differences in IC-values revealed a high sensitivity/specificity of 96.7%/81.8%. IC and VPCT-parameters showed strong, positive correlations. Mean volume CT dose index for VPCT was 63.4 mGy and 4.9 mGy for iodine maps.

CONCLUSION: Thus, IC is a meaningful perfusion marker for local therapy response monitoring in HCC that can be acquired with low radiation dose. This information is important for further therapy response applications using dual and single energy CT.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Thaiss WM, Haberland U, Kaufmann S, et al. Dose Optimization of Perfusion-derived Response Assessment in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: Comparison of Volume Perfusion CT and Iodine Concentration. Acad Radiol. 2018. PMID: 30482626. doi:10.1016/j.acra.2018.09.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。